Salix Press Release

07/01/2014 - 07:15 Salix Announces Statistically Significant Primary Endpoint Result For Target 3 Evaluating The Efficacy And Safety Of Repeat Treatment With Rifaximin 550mg In Subjects With Irritable Bowel Syndrome With Diarrhea
06/12/2014 - 15:36 FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC
05/28/2014 - 06:36 Salix Pharmaceuticals To Present At Three Investment Conferences In June
05/06/2014 - 04:13 Salix Pharmaceuticals to Present at Two Investment Conferences in May
05/05/2014 - 06:09 Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2014
04/24/2014 - 06:05 Salix Pharmaceuticals Announces 1Q2014 Financial Results Conference Call and Webcast
04/22/2014 - 04:27 Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of Relistor in Chronic Non-Cancer Pain by the European Medicines Agency
03/04/2014 - 10:08 Salix Pharmaceuticals To Present At ROTH Conference
02/27/2014 - 11:06 Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
02/25/2014 - 13:03 Salix Wins Napo Pharmaceuticals Litigation
02/13/2014 - 08:07 Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results Conference Call and Webcast
02/04/2014 - 06:08 Salix Pharmaceuticals Announces Issuance of U.S. Patent for Rifaximin
01/30/2014 - 18:02 Salix Announces Acceptance of NDA Filing For Budesonide Foam in Patients with Distal Ulcerative Colitis
01/14/2014 - 09:53 Fulyzaq® (crofelemer) 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy
01/13/2014 - 09:48 Salix Pharmaceuticals Provides Post-Merger Update
01/08/2014 - 07:48 Advancing Treatment in Gastroenterology™
01/02/2014 - 14:57 Salix Pharmaceuticals Completes Acquisition of Santarus
12/10/2013 - 07:49 Salix Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Santarus
12/03/2013 - 06:49 Salix Pharmaceuticals Commences Cash Tender Offer for All Outstanding Shares of Santarus
11/18/2013 - 08:48 Salix Announces Approval of Additional Injection Techniques for DEFLUX®
11/07/2013 - 14:51 Salix Pharmaceuticals to Acquire Santarus
11/01/2013 - 05:09 Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting
10/24/2013 - 06:57 Salix Pharmaceuticals Announces 3Q2013 Financial Results Conference Call and Webcast
10/14/2013 - 09:01 Ulcerative Colitis For Dummies® Now Available Online
10/11/2013 - 09:01 Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2013 Annual Scientific Meeting
09/04/2013 - 15:52 Salix Pharmaceuticals Previews PAINWeek® Presentation
08/20/2013 - 03:48 Salix Pharmaceuticals Announces Call for Full Redemption of Senior Convertible Notes
07/25/2013 - 08:24 Salix Pharmaceuticals Announces 2Q2013 Financial Results Conference Call and Webcast
07/03/2013 - 07:12 Salix Pharmaceuticals to Present at JMP Securities Healthcare Conference
05/30/2013 - 07:12 Salix Pharmaceuticals Acquires Worldwide Rights To Olon’s Intellectual Property Relating To Amorphous Rifaximin
05/22/2013 - 07:12 Salix Pharmaceuticals Announces Statistically Significant Results For Budesonide Foam In The Treatment Of Active Mild To Moderat
05/09/2013 - 07:11 Salix Pharmaceuticals Reports 1Q2013 Results
05/07/2013 - 07:11 Salix Pharmaceuticals To Present At BofA Merrill Lynch 2013 Health Care Conference
Copy and paste this code to display this page on your website .
Syndicate content